ALK-Abelló A/S ALK-B.CO
Nasdaq Copenhagen · Healthcare · Biotechnology
242.80 DKK
−1.5%
2026-11-06
Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.
Annual accounts for ALK-Abelló
| DKK million | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 4,511 | 4,824 | 5,537 | 6,312 |
| EBITDA | 709 | 914 | 1,394 | 1,994 |
| Net income | 335 | 486 | 815 | 1,197 |
| Balance sheet | ||||
| Equity | 3,988 | 4,447 | 5,373 | 6,445 |
| Total debt | 696 | 765 | 1,187 | 418 |
| Cash | 221 | 474 | 589 | 1,240 |
| Net debt | 475 | 291 | 598 | −822 |
| Ratios and per share | ||||
| EBITDA margin | 15.7% | 18.9% | 25.2% | 31.6% |
| Profit margin | 7.4% | 10.1% | 14.7% | 19.0% |
| Return on equity | 8.4% | 10.9% | 15.2% | 18.6% |
| Earnings/share (DKK) | 1.52 | 2.20 | 3.68 | 5.40 |
| Book value/share (DKK) | 18.05 | 20.10 | 24.27 | 29.09 |
| Shares outstanding (M) | 221 | 221 | 221 | 222 |
From the annual statements (Yahoo Finance), in the currency the company reports in. Per-share figures use the shares at the year end. Charts and annual figures →
Key figures
| P/E | 44.9 |
| P/B | 8.3 |
| EV / EBITDA | 26.6 |
| Net debt / EBITDA | −0.4 |
| Return on equity | 18.6% |
| Profit margin | 19.0% |
| Beta 1Y | 0.40 |
| Revenue growth 1Y | +14.0% |
| Revenue CAGR 3Y | +11.8% |
| Earnings/share CAGR 3Y | +52.7% |
| ROE avg. 3Y | 14.9% |
Ratios use the latest annual report that was public 90 days after the year end.
Dividends per share (DKK)
| 2026 | 1.60 |
Not investment advice. Figures may contain errors from the data source.